Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rika Harabayashi"'
Autor:
Norihiro Sakurai, Hiroshi Kakeya, Rika Harabayashi, Tsubasa Yano, Katsuya Nagayama, Koichi Yamada, Yasutaka Nakamura
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 45:576-583
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a481a8ab12e2838b792761e55f4f4ee
https://doi.org/10.5649/jjphcs.45.576
https://doi.org/10.5649/jjphcs.45.576
Autor:
Mikihisa Takano, Ryoko Yumoto, Risako Harada, Mioka Miyamoto, Rika Harabayashi, Masashi Kawami
Publikováno v:
Lung. 194:923-930
Methotrexate (MTX) therapy of certain cancers and rheumatoid arthritis often induces serious interstitial lung complications including pulmonary fibrosis. In this study, we investigated the epithelial–mesenchymal transition (EMT) induced by MTX and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::147d84e3cb65ff5cc4970c3547ba89c8
https://doi.org/10.1007/s00408-016-9935-7
https://doi.org/10.1007/s00408-016-9935-7
Autor:
Rika Harabayashi, Mikihisa Takano, Ryoko Yumoto, Risako Harada, Yohei Yamagami, Masashi Kawami
Publikováno v:
Biochemical and biophysical research communications. 497(1)
Methotrexate (MTX) often induces serious lung diseases such as pulmonary fibrosis. Although MTX is known to be a folic acid (FA) antagonist, the effect of FA on MTX-induced lung injury remains unclear. Recent studies indicate that epithelial-mesenchy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b51b90f3728a8ec8bde005b3596e66
https://pubmed.ncbi.nlm.nih.gov/29448106
https://pubmed.ncbi.nlm.nih.gov/29448106